Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Arbutus Biopharma Corp | Financial_Report.xls |
| 10-Q - FORM 10-Q - Arbutus Biopharma Corp | f10q_081314.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exh_311.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exh_312.htm |
| EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exh_322.htm |
| EX-10.2 - EXHIBIT 10.2 - Arbutus Biopharma Corp | exh_102.htm |
| EX-10.1 - EXHIBIT 10.1 - Arbutus Biopharma Corp | exh_101.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Tekmira Pharmaceuticals Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.
|
Date: August 14, 2014
|
/s/ Mark Murray
|
||
|
Name:
|
Mark Murray
|
|
|
Title:
|
President and Chief Executive Officer
|
|